Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine (Q44407173)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 26, 2003

Language	Label	Description	Also known as
English	Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine	scientific article published on March 26, 2003

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine (English)

1 reference

Europe PubMed Central

2 December 2017

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine (English)

1 reference

10.1038/SJ.NPP.1300157

https://api.crossref.org/works/10.1038/SJ.NPP.1300157

25 December 2023

0 references

1 reference

10.1038/SJ.NPP.1300157

https://api.crossref.org/works/10.1038/SJ.NPP.1300157

25 December 2023

Jeffrey Lieberman

1

object named as

Jeffrey A Lieberman

1 reference

Europe PubMed Central

2 December 2017

author name string

Michael Phillips

2

1 reference

Europe PubMed Central

2 December 2017

Hongbin Gu

3

1 reference

Europe PubMed Central

2 December 2017

Scott Stroup

4

1 reference

Europe PubMed Central

2 December 2017

Peiyan Zhang

5

1 reference

Europe PubMed Central

2 December 2017

Lan Kong

6

1 reference

Europe PubMed Central

2 December 2017

Zhongfu Ji

7

1 reference

Europe PubMed Central

2 December 2017

Gary Koch

8

1 reference

Europe PubMed Central

2 December 2017

Jeffrey A. Lieberman

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12700715

25 December 2023

Robert M. Hamer

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12700715

25 December 2023

language of work or name

0 references

publication date

26 March 2003

1 reference

Europe PubMed Central

2 December 2017

full work available at URL

https://www.nature.com/articles/1300157.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12700715

25 December 2023

http://www.nature.com/articles/1300157.pdf

Portable Document Format

1 reference

10.1038/SJ.NPP.1300157

https://api.crossref.org/works/10.1038/SJ.NPP.1300157

25 December 2023

http://www.nature.com/articles/1300157

1 reference

10.1038/SJ.NPP.1300157

https://api.crossref.org/works/10.1038/SJ.NPP.1300157

25 December 2023

Neuropsychopharmacology

1 reference

Europe PubMed Central

2 December 2017

28

1 reference

Europe PubMed Central

2 December 2017

5

1 reference

Europe PubMed Central

2 December 2017

995-1003

1 reference

Europe PubMed Central

2 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300157

0 references

Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Early detection strategies for untreated first-episode psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Time course and biologic correlates of treatment response in first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

A selective review of recent North American long-term followup studies of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Duration of untreated psychosis: a critical examination of the concept and its importance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Reliability and validity of the Chinese versions of the Scales for Assessment of Positive and Negative Symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

The evaluation and treatment of first-episode psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

21 January 2018

West London first-episode study of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

7 January 2021

based on heuristic

inferred from DOI database lookup

Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised controlled trial of prophylactic neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of psychosis and outcome in first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

7 January 2021

based on heuristic

inferred from DOI database lookup

Course of treatment response in first-episode and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

7 January 2021

based on heuristic

inferred from DOI database lookup

13. Early intervention with neuroleptics may decrease the l long-term morbidity of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300157

7 January 2021

based on heuristic

inferred from DOI database lookup

American Journal of Psychiatry

1

156

1686

author name string

DB Allison

publication date

1999

1 reference

10.1038/SJ.NPP.1300157

https://api.crossref.org/works/10.1038/SJ.NPP.1300157

25 December 2023

American Journal of Psychiatry

13

154

4

author name string

MI Herz

publication date

1997

1 reference

10.1038/SJ.NPP.1300157

https://api.crossref.org/works/10.1038/SJ.NPP.1300157

25 December 2023

Identifiers

10.1038/SJ.NPP.1300157

0 references

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44407173&oldid=2038668963"